(Q34656261)

English

Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy (English)

1 reference

Europe PubMed Central

3 August 2017

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

author name string

Aylin A Riedel

1

1 reference

Europe PubMed Central

3 August 2017

Herbert Heien

2

1 reference

Europe PubMed Central

3 August 2017

Jenifer Wogen

3

1 reference

Europe PubMed Central

3 August 2017

Craig A Plauschinat

4

1 reference

Europe PubMed Central

3 August 2017

language of work or name

0 references

publication date

1 August 2007

1 reference

Europe PubMed Central

3 August 2017

Pharmacotherapy

1 reference

Europe PubMed Central

3 August 2017

27

1 reference

Europe PubMed Central

3 August 2017

8

1 reference

Europe PubMed Central

3 August 2017

1102-1110

1 reference

Europe PubMed Central

3 August 2017

Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Economic costs of diabetes in the US in 2002.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co‐administered with metformin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Practical considerations on the use of the Charlson comorbidity index with administrative data bases

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

The burden of treatment failure in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Treatment escalation and rise in HbA1c following successful initial metformin therapy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1102

21 January 2018

Identifiers

10.1592/PHCO.27.8.1102

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34656261&oldid=1990230565"